Om Megashree Pharmaceuticals to Convene SGM for Strategic Acquisition of Royal Pharmaceuticals

Om Megashree Pharmaceuticals Limited (OMPL) has announced its decision to convene a Special General Meeting (SGM) on 28th Ashadh, 2083 (approximately mid-July 2026), at 09:00 AM. This pivotal meeting is scheduled to take place at the Company Industrial Premises, Jugedi, Bharatpur Metropolitan City–29, Chitwan. The SGM marks a significant strategic juncture for OMPL, as its primary agenda centers around the proposed acquisition of Royal Pharmaceuticals Pvt. Ltd., a move that could substantially reshape its market presence and operational capabilities within Nepal's pharmaceutical sector.

The book closure date for the SGM has been set for Ashadh 22, 2083. This crucial deadline dictates that only shareholders who hold OMPL shares on or before this specific date will be eligible to attend the meeting and cast their votes on the resolutions presented. An SGM is typically called to seek shareholder approval for major corporate actions that fall outside the regular scope of an Annual General Meeting (AGM), particularly those involving substantial financial commitments or strategic shifts like mergers and acquisitions, which require explicit shareholder mandate.

The comprehensive agenda for the upcoming SGM underscores the meticulous planning and regulatory compliance involved in this significant acquisition. Key items slated for shareholder deliberation and approval include:

1. Approval of the Acquisition Proposal: Shareholders will be asked to vote on the board's proposal to acquire Royal Pharmaceuticals Pvt. Ltd. This is the foundational resolution, without which the entire acquisition process cannot proceed.
2. Ratification of Prior Actions: The meeting will seek to ratify all actions, decisions, regulatory communications, and procedures completed to date in relation to the acquisition process. This ensures legal and procedural compliance, providing retrospective shareholder endorsement for steps already taken.
3. Due Diligence and Valuation Approval: A critical agenda point involves the approval of the Due Diligence Audit (DDA) report, the asset and liability valuation report, and the recommended share swap ratio. These reports, prepared by independent valuers, are fundamental in determining the fair value of Royal Pharmaceuticals and establishing the equitable terms of the share exchange, which directly impacts the value received by Royal Pharmaceuticals' shareholders and the potential dilution for OMPL's existing shareholders.
4. Approval of Definitive Documents: Shareholders will be asked to approve the final Memorandum of Understanding (MoU), the detailed acquisition plan, the integrated business plan, and all other related documents that formalize the terms and conditions of the acquisition.
5. Share Issuance and Allocation: A crucial step will be the approval to issue and allocate shares of Om Megashree Pharmaceuticals to the shareholders of Royal Pharmaceuticals, based on the agreed-upon and approved share swap ratio. This effectively integrates the ownership of the acquired entity into OMPL's shareholding structure.
6. Capital Structure Adjustments: Post-acquisition, there may be a need to amend OMPL's authorized capital, issued capital, paid-up capital, and overall shareholding structure. Furthermore, any necessary changes to the company's Memorandum and Articles of Association will also require shareholder approval to reflect the new corporate structure and objectives.
7. Board Authorization for Regulatory Compliance: The board of directors will seek authorization to make any necessary changes, revisions, and implement directives issued by regulatory bodies, including relevant government agencies. This ensures the company can adapt swiftly to any unforeseen regulatory requirements during the integration phase.
8. Comprehensive Authority for Board: Finally, the board will be granted full authority to complete all documentation, seek necessary approvals, manage listing procedures, dematerialization (Demat) of shares, record amendments, and execute all other essential procedures related to the successful completion and integration of the acquisition.

This strategic acquisition, if approved, is poised to significantly enhance Om Megashree Pharmaceuticals' footprint in the competitive pharmaceutical sector. By integrating Royal Pharmaceuticals, OMPL could potentially expand its product portfolio, gain access to new markets, leverage operational synergies, and achieve greater economies of scale. Investors will be keenly watching the outcome of this SGM, as a successful acquisition could lead to increased market share, improved financial performance, and enhanced shareholder value for OMPL in the long run. The detailed planning and comprehensive agenda reflect OMPL's commitment to a structured and compliant acquisition process, aiming to solidify its position as a leading player in the Nepali pharmaceutical industry.